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ARTICLE
Macrophage-derived IL-1β/NF-κB signaling
mediates parenteral nutrition-associated
cholestasis
Karim C. El Kasmi1,2,8, Padade M. Vue1,2,9, Aimee L. Anderson1,2, Michael W. Devereaux1,2, Swati Ghosh1,2,
Natarajan Balasubramaniyan1,2, Sophie A. Fillon1,2, Carola Dahrenmoeller1,2,3, Ayed Allawzi4, Crystal Woods1,2,
Sarah McKenna5, Clyde J. Wright5, Linda Johnson6, Angelo D’Alessandro4,7, Julie A. Reisz 4,7,
Eva Nozik-Grayck4, Frederick J. Suchy1,2 & Ronald J. Sokol1,2
In infants intolerant of enteral feeding because of intestinal disease, parenteral nutrition may
be associated with cholestasis, which can progress to end-stage liver disease. Here we show
the function of hepatic macrophages and phytosterols in parenteral nutrition-associated
cholestasis (PNAC) pathogenesis using a mouse model that recapitulates the human
pathophysiology and combines intestinal injury with parenteral nutrition. We combine
genetic, molecular, and pharmacological approaches to identify an essential function of
hepatic macrophages and IL-1β in PNAC. Pharmacological antagonism of IL-1 signaling or
genetic deficiency in CCR2, caspase-1 and caspase-11, or IL-1 receptor (which binds both IL-1α
and IL-1β) prevents PNAC in mice. IL-1β increases hepatocyte NF-κB signaling, which inter-
feres with farnesoid X receptor and liver X receptor bonding to respective promoters of
canalicular bile and sterol transporter genes (Abcc2, Abcb11, and Abcg5/8), resulting in
transcriptional suppression and subsequent cholestasis. Thus, hepatic macrophages, IL-1β, or
NF-κB may be targets for restoring bile and sterol transport to treat PNAC.
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Parenteral nutrition-associated cholestasis (PNAC), alsoknown as intestinal failure-associated liver disease, is animportant and life-threatening complication of chronic
parenteral nutrition (PN) therapy in infants, children, and adults
with significantly compromised intestinal function and enteral
feeding intolerance1–5. In adults, PN-associated cholestasis,
hepatic steatosis, and hepatic fibrosis progress to cirrhosis within
3–5 years of chronic PN, whereas this progression to end-stage
liver disease is markedly accelerated to 6–12 months in infants
and young children affected by short bowel syndrome, necrotiz-
ing enterocolitis, or other causes of intestinal failure5–11. Thus,
PNAC has historically been the leading indication for multi-
visceral organ transplantation (liver, intestine, other abdominal
organs) in children5,7–13. A major impediment to the develop-
ment of effective preventative and treatment strategies has been a
lack of understanding of PNAC pathogenesis. Clinical studies
have suggested contributing roles of the absorption of bacterial
products, such as lipopolysaccharides (LPS), from compromised,
inflamed intestine, and hepatic retention of phytosterols (plant
sterols), components of intravenous soybean lipid emulsions14. In
fact, the only beneficial therapies for PNAC in children have been
strategies to modify the composition and amount of intravenous
lipid emulsions administered, all of which have in common a
lower phytosterol intake14–24. To explore the mechanisms
underlying PNAC, we have developed a PNAC mouse model in
which mice are exposed to continuous PN infusion for 7–28 days
subsequent to induction of intestinal injury with dextran sulfate
sodium (DSS), recapitulating the human pathophysiology in
infants and adults that develop progressive PNAC. In this model,
we have demonstrated the development of cholestasis, liver
injury25,26, and hepatic macrophage accumulation, key features
observed in the human infant with PNAC27,28. Importantly,
neither intestinal injury nor PN alone were sufficient to induce
PNAC in mice25,26, corroborating the clinical observation that the
most severe expression of PNAC occurs in infants with intestinal
failure29,30. PNAC in mice was associated with reduced hepatic
gene expression of canalicular transporters of bile salts (BSEP
encoded by Abcb11), bilirubin (MRP2, encoded by Abcc2), and
phytosterols (the heterodimer sterolin1 and sterolin2, encoded by
Abcg5 and Abcg8)25,26. In addition, increased portal vein LPS
concentrations were associated with increased transcription of
pro-inflammatory cytokines interleukin-6 (IL-6), tumor necrosis
factor (TNF), and interleukin-1 (IL-1) in purified CD11b+
hepatic macrophages25. Both PNAC and hepatic macrophage
activation were attenuated in mice with genetic deficiency in
TLR4 signaling or in wild-type mice receiving broad-spectrum
enteral antibiotics25. Finally, PNAC, macrophage activation, and
reduced expression of canalicular transporters were attenuated
when PN was devoid of phytosterols, while inclusion of stig-
masterol (a key phytosterol in soy lipid emulsions) into otherwise
phytosterol-free PN restored liver injury, cholestasis, and mac-
rophage activation, implicating phytosterols in PNAC
pathogenesis26.
To further elucidate the molecular and cellular mechanisms in
the pathogenesis of PNAC, in the present study we combine
genetic, molecular, and pharmacological approaches to demon-
strate an essential role for macrophage-derived IL-1β as a key
cytokine in PNAC, activating hepatocyte NF-κB, which in turn
interferes with farnesoid X receptor (FXR) and liver X receptor
(LXR) signaling to result in transcriptional suppression of bile
and sterol transporters, culminating in cholestasis. These
mechanistic insights suggest that hepatic macrophages, hepatic
IL-1β or NF-κB signaling may be new targets for restoring bile
and sterol transport to treat PNAC.
Results
Role of hepatic macrophages in PNAC. We had demonstrated
that treatment of adult C57BL/6 mice with 2.5% DSS in drinking
water for 4 days followed by infusion with total PN containing
soy lipid emulsion for 7–28 days (DSS/PN mice) induced cho-
lestasis and hepatocyte injury. Furthermore DSS/PN mice had
increased portal vein LPS concentrations and increased cytokine
transcription in purified CD11b+ liver macrophages (a finding
consistent with activation of recruited macrophages)31. We also
reported that stigmasterol activated transcription of pro-
inflammatory cytokines in CD11b+ liver macrophages in vivo
in PNAC mice and in vitro in bone marrow-derived mouse
macrophages26. Together, these findings suggested an important
role for macrophages in PNAC14. We first undertook a time-
course experiment and a genetic approach to assess macrophage
accumulation in the PNAC model. Studies in inflammatory liver
injury, including other models of cholestasis, indicate a role for
recruited macrophages, which typically express CD11b and
CCR2, the cognate receptor for MCP1 (encoded by Ccl2), a major
macrophage chemo-attractant, in contrast to resident macro-
phages which express F4/8032,33. We examined hepatic mRNA
expression of Ccl2, Ccr2, Itgam (encoding CD11b) and Emr1
(encoding the pan macrophage marker F4/80) in DSS-pretreated
mice infused with PN for 3, 7, and 14 days relative to controls
(untreated chow mice and DSS-pretreated mice not PN infused).
In DSS/PN mice, we found significantly increased expression of
all four macrophage markers (Supplementary Fig. 1A) and that
Itgam and Emr1 had highest expression on day 3 of PN, prior to
the onset of cholestasis (Supplementary Fig. 1A). We next
employed immunohistochemistry and flow cytometry to analyze
liver of DSS and DSS/PN mice at 3 days, the time point with
highest transcriptional increase in Itgam and Emr1. Consistent
with the gene expression data, there was an expansion of F4/80-
CD11b double-positive macrophages in DSS and DSS/PN mice
relative to chow mice (Supplementary Fig. 1B). Our previous
report had shown increased cytokine transcription in purified
CD11b+ liver macrophages (consistent with activation of
recruited macrophages) from DSS/PN mice25. Because Ccr2−/−
mice lack recruitment of pro-inflammatory macrophages to the
liver34,35, we exposed Ccr2−/− mice to DSS/PN3d and found
significantly reduced F4/80 staining in the liver of Ccr2−/− mice
(Supplementary Fig. 1D). To determine if this reduction in
hepatic macrophages in Ccr2 −/− DSS/PN3d mice protected the
mice from PNAC, we compared DSS/PN14d wild-type (WT)
mice to Ccr2−/− mice and included control groups of DSS/chow
mice, PN-only mice and unmanipulated mice (chow mice) (see
Methods for detailed description of the PNAC mouse model).
Cholestasis was defined by increased serum bilirubin and bile acid
concentrations relative to untreated chow mice and hepatocyte
injury by increased serum alanine-aminotransferase (ALT) and
aspartate-aminotransferase (AST). As reported in the 7-day
PNAC model25,26, only the combination of intestinal injury with
PN infusion (DSS/PN mice) resulted in PNAC in this 14-day
model in WT mice (Fig. 1a). Concomitant with biochemical
cholestasis, mRNA expression of Abcb11 and Abcc2 was sig-
nificantly suppressed in DSS/PN14d mice (Fig. 1a). Similarly,
mRNA expression of Nr1h4, encoding the transcription FXR that
transactivates Abcb11 and Abcc236,37, was suppressed in WT DSS/
PN mice (Fig. 1b). Consistent with findings in the DSS/PN3d
mice, hepatic expression of genes representing recruited and
inflammatory macrophages (Ccr2, Itgam (encoding CD11b), and
Ly6c) was significantly increased in PNAC mice (Fig. 1c) and
immunohistochemistry with F4/80, a pan macrophage marker38,
revealed markedly increased numbers of enlarged (as a sign of
activation) macrophages in livers from WT PNAC mice. These
biochemical, histochemical, and molecular findings in DSS/
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PN14d mice were markedly suppressed in Ccr2−/− DSS/PN14d
mice (Fig. 1d and Supplementary Fig. 1C, D), indicating that
CCR2+ macrophages recruited to the liver were a critical factor
for development of PNAC. Based on these observations, we
hypothesized that inflammatory pathways associatsed with mac-
rophage activation suppressed expression of bile transporters
accounting for biochemical cholestasis and liver injury.
IL-1β suppresses bile transporter expression in PNAC. To test
this hypothesis, we examined if there was a temporal relationship
between development of liver injury, cholestasis, decreased
expression of canalicular transporters, and increased hepatic
cytokine expression. Eight-week-old male C57BL/6 mice pre-
treated with DSS (as in Fig. 1) were randomized into groups
receiving PN for 3, 7, and 14 days. Control groups treated for 3, 7,
and 14 days included DSS/chow, PN-only mice, and chow-fed
mice. Serum total bilirubin and bile acids were not altered in the
3-day DSS/PN mice, but were elevated at 7 days and more pro-
nounced at 14 days (Fig. 2a). Similarly, AST and ALT were not
elevated in 3-day DSS/PN mice but were significantly elevated
after 7 and 14 days of PN (Fig. 2a). Neither cholestasis nor
hepatocyte injury developed in PN-only or DSS/chow mice at any
time point (Fig. 2a). Hepatic mRNA expression of Abcb11 and
Abcc2 was suppressed in DSS/PN mice at 3 days, preceding evi-
dence of cholestasis and hepatocyte injury, and were progressively
suppressed by 14 days (Fig. 2b). Interestingly, in DSS/chow mice
there was moderate suppression of Abcb11 mRNA at the 14-day
time point and suppression of Abcc2 mRNA at the 7-day and 14-
day time points (Fig. 2b), yet, importantly, this reduced trans-
porter expression alone was insufficient to cause cholestasis.
We next measured mRNA expression of Il1b, Tnfa, and Il6
(shown by us to be upregulated in hepatic macrophages in mice
with PNAC25,26) by quantitative PCR (qPCR) in both livers and
in isolated intrahepatic mononuclear cells (IHMCs) at these time
points. Expression of Il1b mRNA was modestly increased in
IHMCs from DSS/chow mice relative to chow controls at day 3
and declined back to control levels by day 14. In contrast, Il1b
transcription in IHMCs from DSS/PN mice was increased
significantly higher at day 3 compared to DSS/chow mice and
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Fig. 1Mice with genetic Ccr2 deficiency are protected from PNAC. a Peripheral serum aspartate-aminotransferase (AST), alanine-aminotransferase (ALT),
and total bile acid concentrations in completely unmanipulated mice (chow), DSS-pretreated mice without any further manipulation, (DSS/chow) wild-type
(WT) DSS-pretreated mice infused with PN (DSS/PN), PN infused wild-type mice without DSS pretreatment (PN only), and Ccr2−/− DSS-pretreated mice
infused with PN (Ccr2−/− DSS/PN). b Liver mRNA from the same groups of mice as in a of genes encoding BSEP (Abcb11), MRP2 (Abcc2), and FXR (Nr1h4)
and c liver mRNA from DSS/PN WT and Ccr2−/− mice of genes encoding CD11b (Itgam), Ly6C, CCR2, and F4/80 (Emr1). d Representative liver
immunohistochemistry for F4/80 from chow, DSS/chow, and DSS/PN mice (black arrows point to F4/80+ cells). *p < 0.05 vs. all other groups by one-
way ANOVA and Tukey's correction (a and c). *p < 0.05 vs. chow, PN only, Ccr2−/− DSS/PN; #p < 0.05 vs. chow by one-way ANOVA and Tukey's
correction (b). Data are depicted from individual mice for serum analysis and means from PCR triplicates from individual mice for gene expression data
±SEM
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remained elevated through day 14 (Fig. 2c). Similarly, Il1b mRNA
was modestly increased in liver homogenate in DSS/chow mice at
day 3 and declined back to chow control levels by day 7, while
elevated Il1b mRNA was robust and sustained through day 14 in
DSS/PN (Fig. 2d). Expression of Il6 was not significantly different
from controls (not shown). The increased hepatic Il1b mRNA in
DSS/PN14d mice was accompanied by markedly elevated serum
concentrations of IL-1β, which were undetectable in PN-only and
DSS/chow mice (Fig. 2e). Finally, expression of hepatic cleaved
caspase-1 protein, essential for production of active IL-1β39, was
increased in DSS/PN14d mice, with a concomitant reduction in
procaspase-1 protein, but not in PN-only mice (Fig. 2f).
The observation that increased transcription of Il1b at 3 days
preceded elevated serum bilirubin, bile acids, AST and ALT
suggested a causative role for IL-1β in the development of
cholestasis (Fig. 2). To determine if IL-1β directly suppressed
hepatic Abcb11 and Abcc2 mRNA in vivo, we injected otherwise
untreated WT mice with 200 ng/mouse recombinant IL-1β
intraperitoneal (i.p.). Compared to untreated mice, within 4 h
of IL-1β exposure there was significant hepatic transcriptional
suppression of Abcb11 and Abcc2 (Fig. 2g). Similarly, in vitro
incubation of primary mouse hepatocytes (Fig. 2h) or the human
hepatocyte cell line HuH7 (Fig. 2i) with IL-1β resulted in
attenuated transcription of both ABCB11/Abcb11 and ABCC2/
Abcc2. These data were consistent with a role for IL-1β
suppression of canalicular transporters in PNAC.
We next determined if LPS, which we had shown to be
increased in portal venous blood in DSS/PN cholestatic mice25,26,
was an upstream signal for inducing macrophage Il1b transcrip-
tion and suppression of hepatic bile transporters. Intraperitoneal
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injection of 2.5 mg/kg LPS into WT mice resulted in increased
Il1b transcription in both liver and isolated IHMCs (Fig. 2j)
coinciding with suppression of hepatic Abcb11 and Abcc2 mRNA
(Fig. 2k). Macrophage depletion was achieved in a separate group
of mice by treatment with clodronate-liposome (Clo-lip),
confirmed by liver F4/80 immunohistochemistry and reduction
of mRNA for Emr1, the gene encoding F4/80 (Supplementary
Fig. 1E, F). In macrophage-depleted mice, LPS injection failed to
both increase hepatic Il1b transcription (Supplementary Fig. 1G)
and to suppress Abcc2 (Fig. 2k). In addition, LPS injection in mice
with interrupted IL-1β signaling (Il1r−/− or Casp1,11−/− mice)
was associated with partially restored Abcc2 expression while
there was no effect on Abcb11 expression (Fig. 2l). Furthermore,
in vitro treatment of HuH7 cells or primary mouse hepatocytes
with LPS for 4 h did not directly suppress either Abcb11 and
Abcc2 mRNA expression (Supplementary Fig. 1H, I). Finally, it
has been suggested that IL-1β can promote TNF expression40–42
and that blocking IL-1 receptor could reduce TNF43 production.
We therefore examined mRNA expression of Tnfa in liver
homogenate and in isolated IHMCs 4 h after LPS injection and
found that LPS was less effective in inducing Tnfa expression in
both liver and purified IHMCs of Il1r−/− mice compared to WT
mice, consistent with the notion that IL-1β signaling can function
upstream of TNFa in a feedforward mechanism (Supplementary
Fig. 1J, K). Together, these findings supported the hypothesis that
in mice with PNAC, liver macrophages were activated by LPS to
produce IL-1β, which, in turn, activated hepatocyte pathways that
suppressed canalicular bile acid and bilirubin transporter
expression.
IL-1β signaling is required for PNAC development. To further
determine if IL-1β played a causative role in PNAC, we employed
mice with genetic deficiency in the IL-1 receptor (Il1r −/−), which
are capable of IL-1β production but unresponsive to IL-1β and
IL-1α signaling44,45. Compared to WT DSS/PN14d mice, Il1r −/−
DSS/PN14d mice were protected from developing PNAC (Fig. 3a)
and hepatic Abcc2 and Abcb11 mRNA were significantly
increased (Fig. 3b). Since Il1r −/− mice are unresponsive to both
IL-1β and IL-1α 44,45, we next used Casp1/11−/− mice (incapable
of generating mature IL-1β)39 to isolate a role for IL-1β and
observed that Casp1/11−/− DSS/PN14d mice did not develop
PNAC (Fig. 3c). We next used pharmacological blockade of IL-1β
as a complementary approach to interrogate IL-1β signaling.
Treatment with intravenous anakinra (Kineret®, Amgen, Thou-
sand Oaks, CA), a commercially available IL-1R antagonist with
significant activity in both mice and humans45, at doses of 25 mg/
kg45 on days 3 and 10 of PN completely prevented PNAC in WT
DSS/PN14d mice (Fig. 3d). Anakinra serum levels at 14 days
measured by enzyme-linked immunosorbent assay (ELISA)45
were comparable to those that had been reported to be sufficient
to suppress IL-1 receptor signaling45 (Fig. 3e). Anakinra treat-
ment of DSS/PN mice prevented the reduction in hepatic gene
expression of Abcb11 and Abcc2 observed in DSS/PN mice treated
with vehicle (Fig. 3f).
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We further examined gene expression of hepatic Nr0b2
(encoding small heterodimer partner (SHP)) and Cyp7a. Induc-
tion of SHP by FXR is an important negative regulator of bile acid
synthesis through suppression of Cyp7a, which encodes the rate
limiting enzyme in bile acid synthesis. In cholestasis, bile acids
that would accumulate in the hepatocyte should transactivate
FXR, increasing SHP which inhibits bile acid synthesis to protect
the hepatocyte from the toxicity of bile acids. In WT DSS/PN
mice, Nr0b2 expression was unexpectedly markedly reduced in
association with moderate reduction (40%) of Cyp7a mRNA
relative to chow mice. In contrast, in Il1r−/−-treated, Anakinra-
treated and Ccr2−/−-treated DSS/PN mice, Nr0b2 expression was
near normal or induced relative to WT DSS/PN mice in
conjunction with stronger suppression of Cyp7a mRNA
(80–90%) (Supplementary Fig. 2A, B). To assess the functional
relevance of these gene expression data, we measured serum
concentrations of taurine-conjugated bile acids by liquid
chromatography-mass spectrometry (LC-MS). Indeed, serum
levels of the major taurine-conjugated bile acids were significantly
increased in WT DSS/PN mice relative to chow mice, while
serum bile acid levels were significantly reduced in Il1r−/− and
CCr2−/− DSS/PN mice, reflecting the Cyp7a expression data
(Supplementary Fig. 2C).
Finally, we undertook experiments to verify that the observed
protection from PNAC in the mice with the various gene
knockouts was not due to differences in intestinal inflammation
and intestinal permeability. We exposed WT mice and the
respective knockout mice (i.e., I11r−/−, Casp1−/−, and Ccr2−/−)
to DSS treatment (DSS in drinking water for 4 days, followed by
2 days of chow, which represents the time point at which PN
infusion would begin) and compared the colon phenotype using
several validated parameters: first we visualized colitis clinically
by observing the occurrence of bloody stools, which was similar
in all DSS-treated mice, regardless of genotype (Supplementary
Fig. 3A). Second, measurement of colon length (as an indicator of
colitis) showed significantly shorter colons in all DSS-treated
mice, regardless of genotype (Supplementary Fig. 3B, C). Third,
colon histology (hematoxylin and eosin and F4/80 stain) showed
similar severe acute inflammation of the cecum characterized by
mucosal and submucosal inflammatory infiltrates, submucosal
edema and expansion of lymphatics, which did not differ among
mice with different genotypes treated with DSS. Specifically, there
was no reduction in colon inflammation in any of the knockout
mice compared toWTDSS-treated mice (Supplementary Fig. 3D).
Finally, intestinal permeability was measured after gavaging DSS-
treated mice with fluorescein isothiocyanate (FITC)-dextran and
determining FITC-dextran concentrations in portal vein serum.
We found significantly increased but similar portal vein FITC-
dextran concentrations (reflecting similar increased intestinal
permeability) in all DSS-treated mice, regardless of genotype,
compared to non-treated mice (Supplementary Fig. 3E). Thus, the
knockout mice used in these DSS/PN experiments had similar
severity of colitis and increased intestinal permeability compared
to the WT DSS/PN mice, discounting the possibility that
differences in intestinal responses to DSS accounted for the
marked differences in cholestasis and hepatic gene expression
among genotypes observed in our experiments.
IL-1β-NF-κB reduces FXR binding to target gene promoters.
We next sought to determine the mechanism by which IL-1β
suppressed hepatocyte Abcb11 and Abcc2 mRNA expression in
this model. As shown in Fig. 1, reduced Abcb11 and Abcc2
expression in WT DSS/PN14d mice was associated with reduced
expression of the gene encoding FXR (Nr1h4), which induces
transcription of these two canalicular transporters36,37 and
reduced nuclear protein levels of FXR relative to chow controls.
In contrast, Il1r −/− and Ccr2−/− DSS/PN14d mice had increased
hepatic Nr1h4 transcription relative to WT DSS/PN mice
(Fig. 4a) and increased FXR protein in the nucleus (Supple-
mentary Fig. 4A). Intraperitoneal injection of LPS into WT mice
suppressed hepatic nuclear FXR protein levels and NR1h4 mRNA
expression. Similarly, i.p. injection of IL-1β (200 ng/mouse, for 4
h) in WT mice suppressed hepatic Nr1h4 transcription in vivo
and in vitro exposure of HuH7 cells and primary mouse hepa-
tocytes to IL-1β (10 ng/ml, for 4 h) suppressed NR1H4/Nr1h4
mRNA levels and nuclear FXR protein levels (Fig. 4b, Supple-
mentary Fig. 4B, C). Nr1h4 mRNA suppression after i.p. injection
of LPS in WT mice was attenuated in mice that had undergone
macrophage ablation with Clo-lip (Fig. 4c) as well as in Il1r−/−
and in Caspase1/11−/− mice (Fig. 4d). Taken together, these
findings support the notion that IL-1β from LPS-activated hepatic
macrophages suppressed hepatocyte Nr1h4 expression and its
translocation to the nucleus.
Based on our reported in vitro findings that NF-κB interferes
with FXR binding to consensus binding sequences in the
promoter of Abcb1146 and considering that IL-1β is a known
inducer of NF-κB signaling, we next determined the role of NF-
κB downstream of IL-1β in suppressing FXR and bile transporter
mRNA expression in PNAC. We first exposed HuH7 cells to
recombinant IL-1β, and demonstrated nuclear translocation of
the NF-κB subunits p50 and p65 at 4 h of exposure. IL-1β-
induced NF-κB activation was further supported by increased
NF-κB luciferase reporter activity and induction of IKBA
expression, a well-known NF-κB target gene (Supplementary
Fig. 4D–F). Furthermore, overexpression of NF-κB p65 in HuH7
cells suppressed ABCC2 mRNA transcription (Supplementary
Fig. 4G) and inhibition of NF-κB p50 subunit increased nuclear
FXR levels in IL-1β-exposed HuH7 cells (Supplementary Fig. 4C).
Pre-incubation with an NF-κB inhibitor for 1 h significantly
increased expression of ABCC2 during a 4-h incubation with IL-
1β; overexpression of an NF-κB repressor also increased ABCC2
expression in IL-1β-treated HuH7 cells (Fig. 4e–f). To determine
if reduced expression of Nr1h4 was associated with reduced FXR
binding and increased NF-κB binding to known consensus
binding sites within the promoter of Abcb11 in vivo in PNAC, we
performed chromatin immunoprecipitation (ChIP) on liver tissue
from chow mice, WT DSS/PN14d mice, and Il1r −/− DSS/PN14d
mice. These experiments showed that binding of FXR to the
Abcb11 promoter was significantly attenuated in WT mice with
PNAC (DSS/PN14d) compared to chow controls, but was
comparable to chow mice in Il1r −/− DSS/PN mice (which were
protected from PNAC) (Fig. 4g). Moreover, binding of NF-κB
p50 and p65 to the Abcb11 promoter was significantly increased
in WT mice with PNAC (DSS/PN14d) compared to chow
controls and was in turn decreased in Il1r −/− DSS/PN mice
relative to WT DSS/PN mice (Fig. 4h). Considering the observed
reduced mRNA expression of Nr1h4 in PNAC mice, we also
performed ChIP assays to examine binding of NF-κB to the
Nr1h4 promoter. Similar to the observations at the Abcb11
promoter, we found binding of p50 and p65 to consensus binding
sites within the Nr1h4 promoter was significantly increased in
WT DSS/PN14d mice compared to chow controls and was
decreased in Il1r −/−DSS/PN mice (Fig. 4h). Intriguingly, binding
of FXR to the Nr1h4 promoter was also significantly attenuated in
WT DSS/PN14d WT mice compared to chow controls and was
similar to chow controls in Il1r−/−DSS/PN mice (Fig. 4h),
suggesting self-regulation of FXR expression in this model. In
summary, IL-1β induced NFκB binding to the promoters of, and
appeared to suppress mRNA expression of, both Nr1h4 and
Abcb11 in the PNAC mice.
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IL-1β-NFκB suppresses sterol transporter expression in PNAC.
We have reported that PNAC was associated with a failure to
transcriptionally induce Abcg5 and Abcg8 encoding the canali-
cular phytosterol transporters, sterolin1 and sterolin226, which
was associated with elevated hepatic and serum levels of intra-
venous soy lipid-derived phytosterols that have been shown to
interfere with FXR signaling18,26,47. Therefore, we hypothesized
that IL-1β also mediated suppression of Abcg5 and Abcg8 (from
here on referred to as Abcg5/8) in PNAC mice. We first compared
hepatic Abcg5/8 expression in DSS/PN14d mice that were either
WT, Il1r−/−, Ccr2−/−, or Anakinra treated. Hepatic Abcg5/8
mRNA was suppressed in WT DSS/PN14d WT mice but was
induced in Il1r−/− Ccr2−/−, and anakinra-treated DSS/PN mice
(Fig. 5a). Similar findings were observed for expression of Nr1h3,
the gene encoding the transcription factor LXR that induces
expression of Abcg5/848 (Fig. 5a). To determine the role of IL-1β
and LPS in this transcriptional suppression, i.p. injection of 200
ng/mouse IL-1β or of 2.5 mg/kg LPS was given to otherwise
untreated WT mice and resulted in significant transcriptional
suppression of Abcg5/8 mRNA in livers of both groups (Fig. 5b).
Deletion of hepatic macrophages by Clo-lip treatment prevented
LPS-induced suppression of Abcg5/8 mRNA in WT mice, as did
use of Il1r−/− or Caspase1/11−/− mice (Fig. 5c), supporting
transcriptional suppression that was promoted by macrophage-
derived IL-1β. Furthermore, in vitro exposure of HuH7 cells and
of primary mouse hepatocytes to IL-1β (2 ng/ml) for 4 h sup-
pressed mRNA levels of NR1H3/ Nr1h3 and ABCG5/8/ Abcg5/8
(Supplementary Fig. 5A; Fig. 5d). ChIP followed by qPCR of liver
tissue from WT DSS/PN14d mice showed increased binding of
p50 and p65 NF-κB subunits, concomitant with reduced binding
of LXR-α (to the LXR-β site), to consensus binding sites within
the Abcg5 promoter as well as Abcg5/8 intergenic region (Fig. 5e).
In contrast, in Il1r−/− DSS/PN14d mice binding of LXR was
increased and that of p50 and p65 was decreased (Fig. 5e); a semi-
quantitative representation is shown in Supplementary Fig. 5B.
Furthermore, in vitro exposure of HuH7 cells to 2 ng/ml IL-1β
reduced nuclear LXR-α protein amounts (Supplementary Fig. 5C)
and in vitro ChIP assays showed reduced binding of LXR-α to the
NR1H3 and ABCG8 promoters concomitant with increased
binding of p50 and p65 subunits (Fig. 5f). Treatment of IL-1β-
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exposed HuH7 cells with an LXR agonist increased LXR binding
and suppressed NF-κB binding to the NR1H3 and ABCG8 pro-
moters (Fig. 5f) and partially reversed the IL-1β-mediated sup-
pression of NR1H3 and ABCG5/8 mRNA levels (Fig. 5d). In
addition, in vitro overexpression of p50 or p65 subunits in HuH7
cells resulted in a dose-dependent suppression of LXR activity
using an LXR reporter construct, while simultaneous over-
expression of an NF-κB repressor increased LXR activity (Sup-
plementary Fig. 5D). Finally, inhibition of NF-κB in HuH7 cells
exposed to 2 ng/ml IL-1β increased mRNA expression of Abcg5/8
and Nr1h3 (Fig. 5g). Taken together, these data support a role for
NF-κB binding to Nr1h3 and Abc5/8 promoters as the mediator
of the IL-1β suppression of Abcg5/8 in PNAC mice.
Finally, we determined if reduced expression of ABCG5/8 is
permissive for phytosterols to interfere with FXR target gene
expression. We used a small interfering RNA (siRNA) approach
to reduce expression of ABCG8 in HepG2 cells (resulting in ~90%
reduction in mRNA for ABCG8, Supplementary Fig. 5E, F),
which were subsequently exposed to an FXR agonist (GW4064, 5
μM; Tocris Bioscience, UK) combined with stigmasterol acetate
(10 μM), a phytosterol with excellent solubility26,47 and shown by
us to promote PNAC and by others to suppress FXR
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Fig. 5 IL-1β induced NF-κB signaling suppresses LXR and ABCG5/8. a Liver mRNA for Abcg5, Abcg8, and Nr1h3 in WT chow mice relative to WT DSS/PN,
WT PN-only, Ccr2−/−DSS/PN, Il1r−/− DSS/PN, and Anakinra DSS/PN mice. b, c Liver mRNA for Abcg5 and Abcg8 in WT mice left untreated, or IL-1β i.p.
injected (4 h) (upper panels) and in mice LPS i.p. injected (4 h), with or without prior (16 h) i.p. clodronate-liposome (Clo-lip) injection (bottom panels). *p
< 0.05 vs. all other groups using t test (upper panels) or one-way ANOVA and Tukey's correction (lower panels). c Liver mRNA for Abcg5 and Abcg8 in WT
mice left untreated, or i.p. LPS injected relative to that Casp1/11−/− and Il1r−/− mice. d Liver mRNA for Abcg5, Abcg8, and Nr1h3 in untreated mouse primary
hepatocytes relative to LXR agonist (GW3965, 2 μM, 16 h) and IL-1β (additional 4 h) treatment. e qPCR from LXRβ binding site within the ABCG5/8
intergenic region and ChIP for LXRα or NF-κB p65 and p50 on liver homogenate from WT chow, WT DSS/PN, and Il1r−/− DSS/PN mice. Data represented
as fold change over IgG; POLII shown as control. f ChIP from HuH7 cells left untreated (HuH7), or exposed to LXR agonist (GW3965, 2 μM; HuH7+
GW3965) for 16 h with or without additional exposure to IL-1β for 4 h. Specific antibodies for either LXR (left) binding to LXR promoter (top left) or ABCG8
intergenic region (bottom left) or NF-κB p50 and p65 (right) binding to the LXR promoter (top right) or ABCG8 intergenic region (bottom right). g Relative
mRNA in primary mouse hepatocytes for Nr1h3, Abcg5, and Abcg8 exposed to IL-1β (2 ng/ml) with or without prior exposure (1 h) to NF-κB inhibitor (BAY-
11-7082, 50 μM. h mRNA for ABCC2 in HepG2 cells exposed to transfection reagent (vehicle) or control siRNA and ABCG8 siRNA and exposure to FXR
agonist GW4064 (5μM) with and without stigmasterol acetate (20 μM) (d, g, h depict mean ± SEM of technical triplicates from one representative out of
at least five experiments). a, d, g *p < 0.05 vs. all other treatments using one-way ANOVA and Tukey's correction
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signaling18,26,47. The ability of GW4064 to induce transcription of
its target gene ABCC2 was significantly reduced in the presence of
stigmasterol acetate when expression of ABCG8 was suppressed
by siRNA (Fig. 5h). Because of very low expression levels of
ABCB11 (Ct values consistently >36) in HuH7 and HepG2 cells,
we next determined in primary mouse hepatocytes if the
combination of stigmasterol acetate with IL-1β (to mediate
Abcg5/8 suppression) would inhibit the ability of GW4064 to
induce Abcc2 and also Abcb11 transcription. Indeed, while IL-1β
or stigmasterol acetate alone inhibited Abcc2 and Abcb11
transcription that was induced by GW4064, the greatest
suppression of GW4064-induced Abcc2 and Abcb11 transcription
was observed when IL-1β was combined with stigmasterol acetate
(Supplementary Fig. 5F). Thus, reduced expression of ABCG5/8
(either by siRNA or through IL-1β), allowing for hepatocyte
accumulation of stigmasterol acetate, was associated with
antagonism of FXR induction of bile transporters.
Discussion
This study supports the hypothesis that PNAC in mice results
from pro-inflammatory activation of hepatic macrophages by
intestinal-derived LPS25 and circulating phytosterols26 with sub-
sequent generation of IL-1β, which binds to hepatocyte IL-1
receptor and increases NF-κB translocation to the nucleus,
wherein p50 and p65 bind to promoter sequences and suppress
transcription of genes encoding FXR and LXR as well as FXR-
regulated and LXR-regulated genes. The result is significantly
reduced transcription of canalicular transporters of bile acids,
bilirubin, and phytosterols causing phytosterol retention, which
further antagonizes FXR induction of Abcb1118,26,47, culminating
in reduced biliary secretion and hepatic accumulation of bile acids
which cause cholestatic hepatocyte injury (Fig. 6).
This PNAC mouse model was developed and designed in order
to recapitulate the pathophysiology in the human infant and adult
with PNAC, in which short bowel syndrome and other forms of
intestinal injury and inflammation lead to impaired intestinal
barrier function and require the patient to receive PN infusion. It
is only in these patients with intestinal injury and intestinal
failure that PN leads to progressive liver disease and eventual
need for multivisceral transplant. Compounding the altered
intestinal barrier function, the infusion of plant sterol containing
lipid emulsions may activate macrophages and directly suppress
bile transporters15,25,26,29,.We therefore developed our mouse
model to include both intestinal injury/increased permeability
(DSS-induced) and infusion of plant sterol containing PN in
order to mimic the human pathophysiology in those infants and
adults that develop progressive PNAC25,26. In the current
experiments, DSS-induced intestinal injury and inflammation
and LPS absorption were not altered in the various gene knockout
mice that we investigated, indicating that the demonstrated
protection from PNAC in these knockout mice was likely not due
to alterations in the intestinal phenotype but rather a con-
sequence of interfering with inflammatory pathways within the
liver.
Recent human studies analyzing gene expression and histology
of livers from infants with intestinal failure and PNAC have
further validated our mouse model by documenting very similar
findings to those observed in our DSS/PN mouse model15,29. This
includes hepatic macrophage accumulation that was associated
with cholestasis and increased levels of phytosterols, increased
hepatic inflammatory cytokine expression (IL1B, IL6, TNF) in
conjunction with suppression of hepatic sterol transporters
(ABCG5/8), and increased circulating plant sterol concentrations
which coincided with suppression of canalicular bile acid trans-
porters (ABCB11; BSEP) and cholestasis. Furthermore, these
studies in human infants with PNAC demonstrated a relationship
between increased inflammation (on liver histology and liver
mRNA for IL1B, IL6, TNF) and decreased ABCB11 mRNA
expression29. These reports confirm the applicability of this
PNAC mouse model to test the hypotheses put forward in the
present studies.
Our in vivo experiments demonstrated that DSS and DSS/PN
mice had increased accumulation of macrophages that were
F4/80/CD11b double positive when analyzed by FACS, which was
consistent with mRNA data showing increased expression
of hepatic Itgam (encoding CD11b) and Emr1 (encoding F4/80).
F4/80-expressing macrophages have been suggested to mainly
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Fig. 6 Hypothetical model of PNAC pathogenesis. Increased intestinal permeability secondary to intestinal inflammation and dysbiosis promotes increased
absorption of LPS into portal vein with subsequent TLR4-mediated activation25 and caspase-1- dependent generation of IL-1β in recruited CCR2+
macrophages (phytosterols contribute to macrophage activation and IL-1β synthesis)26. Through IL-1 receptor (IL-1R) binding on hepatocytes, IL-1β
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ABCG5/8, ABCB11, and ABCC2, resulting in decreased expression of BSEP, MRP2, and ABCG5/8 (blue downward arrows) and phytosterol retention (green
dots). Retained phytosterols antagonize FXR activity leading to additional reduction in BSEP and MRP2 expression and subsequent retention of bile acids
and bilirubin (additional phytosterol effects indicated by green downward arrows) and cholestasis. In addition, direct effects of LPS on the hepatocyte can
suppress FXR activity (dotted line from LPS to hepatocyte)
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represent resident hepatic macrophages (Kupffer cells), while
CD11b+ macrophages appear to be recruited from circulating
monocytes32. Therefore, macrophages with a double-positive
phenotype could represent a pool of recruited macrophages that
took on the resident phenotype by increasing their expression of
F4/80 and maintaining expression of CD11b, as has been shown
in the lung49. In order to functionally address if macrophage
recruitment played a role in the PNAC model, we took advantage
of mice genetically deficient in Ccr2, which have been used in
other liver injury models to demonstrate a role for recruited
macrophages in liver fibrosis and alcohol-induced liver
injury34,35. We found protection against PNAC in Ccr2−/− mice,
in which we demonstrated evidence of reduced macrophage
accumulation by both F4/80 immunohistochemical staining and
mRNA analysis. These findings are consistent with our previous
report that showed increased cytokine transcription in purified
CD11b+ liver macrophages in mice with PNAC25. Together with
increased hepatic expression of Ccl2 mRNA (the cognate che-
mokine to CCR2), these data suggest an important role for
recruited CD11b+ macrophages in the pathogenesis of PNAC.
More sophisticated future studies will be required to determine
the degree to which recruitment of CCR2+ macrophages con-
tributes to the expansion of F4/80/CD11b macrophages in PNAC.
Our studies have further identified a causal role for
macrophage-derived IL-1β in PNAC as evidenced by increased
Il1b transcription in hepatic mononuclear cells and serum levels
preceding the onset of cholestasis and hepatocyte injury, which
can be prevented through multiple genetic and pharmacological
manipulations to interrupt IL-1β signaling. Furthermore, in vitro
experiments in primary mouse hepatocytes and human hepatoma
cell lines HuH7 and HepG2 together with in vivo experiments
demonstrated that IL-1β exposure was sufficient to suppress
transcription of Nr1h4, Abcb11, Abcc2, and Abcg5/8, findings that
characterize the PNAC liver. Prevention of PNAC in Caspase1/
11-knockout mice, which are incapable of producing mature IL-
1β but can produce IL-1α, verified a role for IL-1β rather than IL-
1α39,44,45. The increased hepatic levels of cleaved caspase-1 pro-
tein (the enzyme required for processing of inactive pro-IL-1β
into active mature IL-1β) in PNAC mice further support the liver
as the source for IL-1β in this model. Importantly, our data
demonstrate that protection from PNAC in the DSS/PN mice
lacking Ccr2, Caspase1/11, or Il1r was not due to differences in
colon inflammation or permeability. All DSS-treated mice
regardless of genotype had similar timing and similar degrees of
development of bloody stools, shortening of colon length, histo-
logical typhlitis, and FITC-dextran absorption into the portal
vein. These data expand our previous findings that demonstrated
the dual requirement of absorbed intestine-derived LPS plus
intravenous administration of soy oil lipid emulsions that are
unique to the pathogenesis of PNAC25,26. Our data suggest that
IL-1β is the dominant cytokine in mediating PNAC, and that
hepatic macrophage activation by gut-derived LPS and sub-
sequent production of IL-1β might be a pathogenic pathway
operative in other liver diseases involving the gut–liver axis45.
However, it must be emphasized that the major difference in
PNAC compared to other gut–liver axis disease models is the
requirement for concomitant intravenous soy oil lipid emulsion
administration in addition to the intestinal injury. In the PNAC
mouse model, absorption of LPS from the intestine is only one of
the factors leading to cholestasis, and importantly, alone is
insufficient in this model to cause PNAC. DSS treatment alone to
WT mice, which resulted in increased intestinal permeability and
increased portal vein LPS concentrations (El Kasmi et al.25 and
Supplementary Fig. 3E), was not associated with cholestasis or
liver injury in our model; however, the sequential combination of
DSS followed by soy lipid emulsion containing PN was required
for the development of PNAC (El Kasmi et al.25 and Fig. 2a,b),
emphasizing the important distinction of PNAC pathogenesis
from LPS/sepsis-mediated cholestasis.
Genetic and pharmacological blockade of IL-1β signaling both
normalized bile transporter expression and attenuated cholestasis
and hepatocyte injury in the PNAC model. Studies in humans
and mice have clearly demonstrated a pivotal role for BSEP and
MRP2 as canalicular transporters of bile acids and bilirubin into
bile, respectively50,51. Disruption of expression of these trans-
porters is pathologic as evidenced by inherited mutations of
ABCB11 and ABCC2 which cause progressive familial intrahe-
patic cholestasis and Dubin–Johnson disease, respectively50–55.
Elevated serum bile acids and bilirubin in the face of transcrip-
tional suppression of Abcb11 and Abcc2 therefore strongly
implicate insufficient expression of BSEP and MRP2 in the
pathogenesis of cholestasis in this model. Moreover, recent
human studies analyzing gene expression and histology of livers
from infants with intestinal failure and PNAC have documented
very similar findings to those observed in our DSS/PN mouse
model15,25,26,29, including the roles of macrophages, phytosterol
levels, FXR and LXR signaling, and canalicular transporters.
Mechanistically, IL-1β appears to mediate cholestasis in PNAC
through hepatocellular NF-κB signaling, which interferes with the
ability of FXR to bind to and transactivate Abcb11 and Abcc2
promoters, thus reducing canalicular bile and bilirubin transport.
Using ChIP in liver tissue from WT DSS/PN 14d mice, we
showed that increased NF-κB binding coincided with decreased
FXR binding to the Abcb11 promoter. Conversely, mice deficient
in the IL-1 receptor showed increased FXR binding and decreased
NF-κB binding to the Abcb11 promoter, which was associated
with normalized Abcb11 expression and attenuation of choles-
tasis. Furthermore, in vitro pharmacological inhibition of NF-κB
increased the expression of Nr1h4, Abcb11, and Abcc2. These
results support the proposed role of NF-κB as an important
mediator of the cholestatic effect of IL-1β in this model and is
consistent with previous reports demonstrating a role of NF-κB in
suppressing FXR signaling and BSEP expression in vitro46.
We also show that mice with PNAC had suppressed SHP
mRNA, and that SHP expression was increased in Il1r−/−,
Anakinra-treated and Ccr2−/− DSS/PN mice that were protected
from PNAC. Concomitantly, we found that Cyp7a expression was
significantly higher in WT DSS/PN mice relative to Il1r−/−,
Anakinra-treated and Ccr2−/− DSS/PN mice. On a functional
level, concentrations (measured by LC-MS) of the major taurine-
conjugated bile acids were significantly increased in WT DSS/PN
mice relative to chow mice, and again significantly reduced in Il1r
−/−, Anakinra-treated and Ccr2−/− DSS/PN mice. We conclude
that reduced expression of SHP in DSS/PN mice (due to reduced
expression and reduced transcriptional activity of FXR) results in
insufficient suppression of Cyp7a with subsequent inadequate
suppression of bile acid synthesis. This maladaptive failure to
downregulate bile acid synthesis in cholestatic DSS/PN mice may
lead to increased bile acid levels and exacerbate the cholestatic
injury, especially in the face of reduced expression of BSEP.
In a 7-day PNAC mouse model, we reported that phytosterols,
specifically stigmasterol, contained within the soy lipid emulsion
component of the PN solution, were a required co-factor neces-
sary for the development of PNAC26. Moreover, stigmasterol
promoted hepatic macrophage activation in vivo and directly
induced transcription of Il1b in vitro in naïve bone marrow-
derived macrophages, thus contributing to the hepatic inflam-
matory milieu in this mouse model26. Stigmasterol has also been
postulated to directly promote cholestasis through antagonizing
FXR activity resulting in reduced Abcb11 expression18,47. Phy-
tosterols are excreted from the hepatocyte through canalicular
sterolin1/2, a heterodimer that has been shown to be the principal
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cholesterol and phytosterol transporter in the hepatocyte56–61. In
the setting of intravenous delivery of phytosterols (e.g. PN infu-
sion), hepatocyte excretion into bile becomes an important dis-
posal pathway for circulating phytosterols29,57–61. In human
infants with intestinal failure who receive PN and develop PNAC,
hepatic ABCB11 and ABCG5/8 mRNA levels were found to be
reduced and elevated serum and hepatic levels of phytosterols
correlated with the severity of hepatic inflammation and choles-
tasis15,16,19,29,62,63. Similarly, significant hepatic and serum stig-
masterol retention was shown by us in the 7-day PNAC mouse
model co-incident with suppressed transcription of Abcb11 and a
failure to induce hepatic Abcg5/8 expression26. Expanding on
these observations, the current study found that Abcg5/8
expression remained significantly reduced at 14 days in PNAC
mice and that IL-1β and downstream NF-κB signaling were
associated with transcriptional suppression of Nr1h3 and Abcg5/
8. ChIP and qPCR analyses confirmed decreased binding of LXR
to consensus binding sites within the promoter of Abcg5/8, both
in vivo in WT DSS/PN14d mice and in vitro in IL-1β treated
HuH7 cells, findings that were reversed in Il1r−/−-treated or
Anakinra-treated DSS/PN mice, as well as upon blockade of NF-
κB signaling in vitro. Similar to the findings with FXR, we found
that the reduced LXR binding to Nr1h3 and Abcg5/8 promoters
was associated with increased binding of NF-κB to these pro-
moters, which was reversed in Il1r−/− DSS/PN14d mice.
Importantly, in vitro inhibition of NF-κB signaling resulted in
increased NR1H3 and ABCG5/8 expression in IL-1β-exposed
HuH7 cells. Finally, siRNA targeted suppression of Abcg5/8
in vitro or co-exposure of primary hepatocytes to IL-1β facilitated
stigmasterol-mediated suppression of Abcc2. These findings
demonstrate an important role for NF-κB in PNAC and further
substantiate the proposed essential role of LXR in driving
expression of Abcg5/846,48.
Taken together, these findings support a mechanism in which
IL-1β acting through NF-κB suppressed nuclear Nr1h4 and Nr1h3
transcription, resulting in both reduced nuclear FXR and LXR
protein levels and activity culminating in reduced bile acid,
bilirubin, and sterol canalicular transport and subsequent reten-
tion of phytosterols and bile acids. Intriguingly, a recent study has
implicated macrophage FXR signaling as a negative regulator in
LPS-mediated IL-1β production in sepsis-associated cholestasis64.
Therefore, increased concentrations of phytosterols (due to their
structural similarity to bile acids) and bile acids as they occur in
the PNAC model could further contribute to the macrophage IL-
1β production through inhibition of macrophage FXR signaling.
Future studies will be directed at interrogating the interplay of
bile acids, phytosterols, and LPS in macrophage activation in
PNAC.
In conclusion, we propose that pharmacological interference
with specific inflammatory signals (e.g., macrophage recruitment
and activation, IL-1β or NF-κB signaling) or modification of lipid
emulsions to avoid or reduce phytosterol levels may have ther-
apeutic value in the prevention and treatment of PNAC.
Methods
PNAC mouse model. All animal procedures described herein were approved by
IACUC of the University of Colorado Anschutz Medical Campus and all animals
were treated humanely throughout the experimental procedures. The PNAC mouse
model25,26 employed C57BL/6 WT adult male mice (8 weeks old, 22–23 g body
weight) (Jackson Laboratories, Bar Harbor, ME, USA) that were housed in specific
pathogen-free conditions in individual metabolic cages and maintained on a 12 h
light/dark cycle. To induce mild intestinal injury and increased permeability25,
mice were exposed ad libitum to 2.5% DSS (MP Biomedicals, Santa Ana, CA, USA)
in the drinking water for 4 days during which time they had access to chow ad
libitum (referred to as “DSS pretreatment”). After DSS pretreatment, PNAC mice
underwent continuous pentobarbital anesthesia during surgical placement of a
central venous catheter (CVC) (Silastic tubing, 0.012 inches internal diameter; Dow
Corning, IL, USA) into the right jugular vein while the proximal end was tunneled
subcutaneously and exited between the shoulder plates. While still under anes-
thesia, mice were subsequently placed in a rubber mouse harness (Instech
Laboratories, Plymouth Meeting, PA, USA) and the CVC was threaded through a
swivel apparatus and connected to an infusion pump (Harvard Apparatus, Hol-
liston, MA, USA). Mice were recovered from anesthesia on a heating pad under
continuous supervision and allowed to further recovery from surgery for 24 h with
intravenous (i.v.) normal saline (NS) infusion at a rate of 0.23 ml/h and were given
ad libitum access to chow and water. After 24 h chow was removed, access to water
was continued and mice were continuously infused for 14 days with PN (DSS/PN
mice) at a rate of 0.29 ml/h providing a caloric intake of 8.4 kcal/day and soybean
lipid emulsion (IntralipidR, Fresenius, Bad Homburg, Germany) dose of 5 g/kg/
day,25,26. Mice were randomly assigned to each of several groups. A subgroup of
DSS-pretreated mice was infused with NS for 14 days instead of PN (DSS/NS
mice). Other mice (PN-only mice) were not DSS pretreated but underwent CVC
placement and received PN in the same manner as DSS/PN mice. DSS-pretreated
mice that did not have a CVC placed were given free access to chow and water for
14 days (DSS/chow mice). All PN infused mice had access to water ad libitum but
not to chow during the PN infusion period. Unmanipulated control mice (referred
to as chow mice) had free access to chow and water for a period of 19 days. In some
experiments DSS/PN, DSS/chow, and chow treatments were given to Ccr2−/−, Il1r
−/−, or Casp1/11−/− mice on the C57BL/6 background (Jackson Laboratories, Bar
Harbor, ME, USA). Pharmacological blockade with the IL-1 receptor antagonist
was achieved by administration of Anakinra (Kineret) 25 mg/kg body weight45
formulated in NS and infused through the CVC on days 3 and 10 of PN infusion in
DSS/PN mice. Anakinra infusion was limited to 1 h, during which PN infusion was
paused. On the day of sacrifice, mice were anesthetized with i.p. pentobarbital and
100–400 µl of blood was collected from the retro-orbital plexus and liver was
removed, one piece placed in formalin for 4 h followed by placement in 70%
alcohol and another piece of liver was snap frozen in liquid nitrogen, coded, and
subsequently stored at −80 °C until analyzed. From all mice similar lobes of liver
were placed in formalin while similar lobes were used for snap freezing to ensure
comparability. Coded serum samples were analyzed by the University of Colorado
Hospital Clinical Chemistry Laboratory for AST, ALT, and total bilirubin levels.
Total serum bile acids were analyzed in coded specimens using a Total Bile Acid
Detection Kit (Diazyme Laboratories, Poway, CA, USA) according to the manu-
facturer’s instructions. All animal procedures were approved by the Institutional
Animal Care and Use Committee.
In vivo LPS and IL-1β exposure. C57BL/6 WT adult male mice (8 weeks old,
22–23 g body weight, identical to the criteria used for PN mice above) (Jackson
Laboratories, Bar Harbor, ME, USA) were injected i.p. with 2.5 mg/kg LPS (from
Escherichia coli 0111:B4; Sigma Aldrich, St. Louis, MO, USA) or with 200 ng/mouse
recombinant mouse IL-1β (BD Biosciences, San Jose, CA, USA) before sacrifice 4 h
later. After sacrifice, liver specimens were placed in formalin and snap frozen in
liquid nitrogen, coded, and stored at −80 °C before RNA extraction.
In vitro cell experiments. Primary mouse hepatocytes were isolated from C57BL/6
WT adult male mice (8 weeks old, 22–23 g body weight) (Jackson Laboratories, Bar
Harbor, ME, USA) using retrograde collagenase (Worthington Biochemical,
Lakewood, NJ, USA) perfusion technique through the right atrium. Hepatocytes
were washed three times and ultimately resuspended in KRH buffer (115 mmol/L
NaCl, 5 mmol/L KCl, 1 mmol/L KH2PO4, 1.2 mmol/L MgSO4, and 25 mmol/L
sodium HEPES), pH 7.4, supplemented with 0.2% bovine serum albumin (Sigma
Aldrich, St. Louis, MO, USA). Initial cell viability as determined by trypan blue
exclusion, and was >90%65. Primary hepatocytes were rested overnight after iso-
lation and stimulated the next day as indicated in the figure legends and text for a
period of 4–24 h. The human hepatocyte cell line HuH7 was cultured in RPMI-
1640 medium (Thermofisher, Waltham, MA, USA) with 10% fetal bovine serum
(FBS) (performance FBS with low endotoxin; Thermo Fisher, Waltham, MA, USA)
and 1% penicillin and 1% streptomycin; Thermo Fisher, Waltham, MA, USA). All
cells were grown in 5% CO2 in a humidified incubator maintained at 37 °C. The cell
lines were obtained from the American Tissue Culture Collection (Manassas, VA,
USA)46. Cells were tested for mycoplasma to ensure absence of contamination each
6 months using MycoAlert Mycoplasma Detection Kit (Lonza, Walkersville, MD,
USA).
HuH7 cells were stimulated with LPS (100ng/ml; Salmonella typhimurium,
Sigma Aldrich, St. Louis, MO, USA) or recombinant human IL-1β (2–10 ng/ml; BD
Biosciences, San Jose, CA, USA) for 4 h in the presence or absence of NF-κB
inhibitor which was pre-incubated for 1 h (50 μM, BAY-11-7085; Cayman
Chemicals, Ann Arbor, MI, USA) or in the presence or absence of an LXR agonist
which was pre-incubated for 1 h (10 μM; T0901317; Tocris, Minneapolis, MN,
USA).
HepG2 cells (ATCC, Manassas, VA, USA) were transfected with control siRNA
or siRNA targeting Abcg8 using DharmaFECT-Duo (Dharmacon, Lafayette, CO,
USA) according to the manufacturer’s protocol. Control siRNA or siRNA targeting
Abcg8 were both designed, synthesized, and prepared by Dharmacon. HepG2 cells
were cultured for 48 h before treatment with 5 μM of the FXR agonist GW4064
(Tocris, Minneapolis, MN, USA) and/or 10 μM stigmasterol acetate (Steraloids,
Newport, RI, USA) for 20 h in same media as HuH7 cells (but containing 0.25%
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serum). HuH7 cells and HepG2 cells were used as cell lines representing human
hepatocytes.
Immunoblot. Immunoblotting of cytosolic and nuclear extracts (using NE-PER™
Nuclear and Cytoplasmic Extraction Reagents according to the manufacturer’s
descriptions; Thermo Fisher) was performed using antibodies for FXR-α (Abbiotec,
cat# 252165, polyclonal rabbit, 1:1000), LXR-α (Thermo Fisher Scientific, cat#
PA1-332, polyclonal rabbit, 1:500) and NFκB p50 (Abcam, cat# ab7971, polyclonal
rabbit, 1:1000), and p65 (Cell Signaling, cat# 8242, monoclonal rabbit, 1:1000)
subunits46. Detection of calnexin (Enzo Life Sciences, cat# ADI-SPA-860, poly-
clonal rabbit, 1:10,000) and lamin B (Santa Cruz Biotechnology, cat# sc-6217,
polyclonal goat, 1:1000) were used to detect potential contamination of cytoplasmic
and nuclear extracts, respectively.
Immunoblotting of total protein extracts from liver homogenate was performed
using M-PER™ Extraction Reagents according to the manufacturer’s descriptions;
Thermo Fisher) using an antibody specific for procaspase-1 and cleaved caspase-1
(Millipore, cat# 06-503, polyclonal rabbit, 1:1000). Anti-GRB2 was used as a
loading control (Cell Signaling, cat# 3972, 1:1000).
The secondary antibodies used for NF-κB subunits p50 and p65, calnexin, and
lamin B are from LiCor Biosciences (Donkey anti-Rabbit, cat# 926-68073, 1:5000;
Donkey anti-Goat, cat# 926-68074, 1:5000). The secondary antibody used for all
other blots was from Cell Signaling (anti-rabbit HRP, cat# 7074S, 1:5000).
Uncropped scans of the blots depicted in the main body of manuscript are shown
in Supplementary Fig. 7.
Immunohistochemistry. Liver and colon tissues were removed at sacrifice, and
then formalin-fixed, paraffin-embedded, and prepared for histology. Slides were
stained with hematoxylin and eosin and the pan macrophage marker F4/80 (clone
BM8; BMA Biomedicals, Rheinstrasse, Switzerland) at a dilution of 1:200. Slides
were treated with a Proteinase K (Invitrogen, cat# 25530–049) antigen retrieval
technique at 20 μg/ml in Tris-EDTA CaCl buffer, pH 8, in a 37 °C water bath for 6
min. Standard immunohistological protocols were used thereafter. Coded slides
were examined and scored in a blinded fashion by a veterinarian pathologist (L.J.).
IL-1β and IL-1 receptor antagonist ELISA. The mouse IL-1βIL-1F2 Quantikine
ELISA Kit (R&D Systems, Minneapolis, MN, USA) and the human IL-1RA
Quantikine ELISA Kit (R&D Systems, Minneapolis, MN, USA) were used
according to the manufacturer’s instructions to detect serum mouse IL-1β and
serum IL-1RA, respectively.
RNA isolation and quantitative gene expression analysis. Liver or cellular RNA
was extracted using TRIzol® (Invitrogen, Carlsbad, CA, USA) according to man-
ufacturer’s instructions. All RNA samples were DNAse treated (Ambion/Applied
Biosystems, Austin, TX, USA) and reverse transcribed with iScript (Bio-Rad,
Hercules, CA, USA). Gene expression was analyzed by quantitative reverse tran-
scription PCR (qRT-PCR) analysis on an Applied Biosystems 7300 or 7500 cycler
and normalized to endogenous control gene Hprt1 (encoding hypoxanthine
phosphoribosyltransferase1). Gene expression is depicted as relative mRNA
amounts (relative quantities (RQ)) after normalization to expression of endogenous
control gene Hprt1 calculated using delta/delta Ct method using the software
provided by Applied Biosystems that comes installed on the7300 or 7500 cyclers.
WT untreated mice or WT chow mice were used as normalizer (RQ set to 1) for
comparison of gene expression in WT mice and chow mice from respective gene-
targeted mice were used as normalizers (RQ set to 1) for comparison of gene
expression in gene-targeted mice. For in vitro experiments, gene expression is
depicted as relative mRNA amounts after normalization to expression of endo-
genous control gene Hprt1 (mouse cells) and HPRT1 (human cell lines) calculated
using delta/delta Ct method as described above and untreated cells were used as
normalizer (set to 1) for comparison of gene expression. PCRs were performed in
technical triplicate for cDNA from each animal and each target gene and Hprt1
shown are averages of the individual means obtained from triplicates. For all gene
expression experiments, samples were analyzed in triplicate using TaqMan probes,
which were designed, tested, optimized, and distributed by Applied Biosystems
(commercially available standardized “TaqMan gene expression assays”). All qRT-
PCR reagents and supplies, including TaqMan mastermix were from Applied
Biosytems, and all procedures were carried out according to protocols and using
software from Applied Biosytems. To verify the fidelity of gene expression results in
this model, for some target genes (Abcg8, Abcb11, Nr1h3, Nr1h4), mRNA
expression was determined using an additional housekeeping gene (Ee2f) side by
side with Hprt1 using cDNA from RNA obtained from liver samples from a
representative group (n= 3–5) of chow and DSS/PN mice with WT, Il1r−/− or
Ccr2−/− genotype in order (Supplementary Fig. 6).
Chromatin immunoprecipitation. ChIP was performed on liver samples that were
immediately flash frozen in liquid nitrogen before processing or on freshly
obtained cell lysates from HuH7 cells46. ChIP was done using specifc antibodies for
FXR (Abbiotech, cat# 252165, rabbit polyclonal), LXRα (Abcam, cat# ab41902,
rabbit polyclonal), LXRβ (Thermo Fisher Scientific, cat# PA1-333, rabbit poly-
clonal), NF-κB p50 (Cell Signaling, cat# 13586, rabbit polyclonal) and NF-κB p65
(Abcam, cat# ab16502, rabbit polyclonal) and amplification of promoter sequences
from the Abcb11, Nr1h3, Abcg5/8, and Nr1h4 genes using specific primer sets and
subsequent PCR; primer sequences will be provided upon request46. ChIP assays
were performed by a combination of protocols and according to the manufacturer’s
instructions using EZ ChIP/MagnaChIP G Kit from EMD/Millipore (Billerica, MA,
USA)46. Cells were harvested after fixation with 1% formaldehyde. After cell lysis
and sonication, the fragmented DNA was diluted in ChIP dilution buffer and pre-
adsorbed with protein G sepharose/salmon sperm DNA (EMD/Millipore, Billerica,
MA, USA) for 1 h at 4 °C. Then 5% of the chromatin was removed and saved as
input. It was then incubated overnight at 4 °C with 3–5 µg of the appropriate
antibodies or normal mouse IgG (Product 12-371 from EMD/Millipore, Billerica,
MA, USA). Antibody–chromatin complexes were captured by incubation with
protein G sepharose and centrifuged. Reversal of protein cross-linking and pro-
teinase K digestion, followed by purification of the DNA, was then achieved. An
aliquot of the DNA (2 µl) was used in a PCR (standard and quantitative) reaction
using specific primers flanking the FXRE, LXRE, or NF-κBE of human ABCG5/8
and LXR promoters. Primers flanking a site distant from the FXRE, LXRE, and NF-
κB sites were used as negative controls. PCR products were run in a 2% agarose gel
and stained with ethidium bromide to confirm the amplicon size.
The method for in vivo ChIP analysis of liver has been modified from protocols
for cells46. Mouse livers were sliced to small pieces and then incubated with 1%
formaldehyde to crosslink proteins to genomic DNA in cells. Following this
incubation, excess formaldehyde was quenched by incubation with glycine.
Chromatin was prepared from cross-linked livers after isolation of nuclei.
Chromatin was sonicated with the appropriate power setting to shear DNA to
approximately ~500 bp fragments for use in ChIP. Uncropped scans of the gels
depicted in main body of manuscript are shown in Supplementary Fig. 7.
UHPLC-MS quantification of bile acids in serum and tissue. A solution of stable
isotope-labeled bile acid standards (50 nM each, all 2,2,4,4-deuterated, Cambridge
Isotope Laboratories, Tewksbury, MA, USA) was prepared in Optima methanol
(Fisher Scientific, Pittsburgh, PA, USA): cholic acid, chenodeoxycholic acid,
deoxycholic acid, glycochenodeoxycholic acid, glycocholic acid, taur-
ochenodeoxycholic acid, taurocholic acid, tauodeoxycholic acid, taurolithocholic
acid, tauroursodeoxycholic acid, and ursodeoxycholic acid. Serum samples were
thawed on ice and extracted at a 1:25 dilution. Frozen tissue samples were weighed
to the nearest 0.01 mg and extracted at 80 mg/mL (liver) or 40 mg/mL (intestinal
content). Samples were agitated at 4 °C for 30 min followed by centrifugation at
10,000 × g for 10 min at 4 °C. Supernatant aliquots from tissue extractions were
diluted with the above MeOH solution to a final concentration of 20 mg/mL.
Supernatants (15 µL for serum; 10 µL for tissue) were injected into a Thermo
Vanquish UHPLC system (San Jose, CA) and run on a Kinetex C18 column (150 ×
2.1 mm2, 1.7 µm; Phenomenex, Torrance, CA, USA) at 300 µL/min. Solvents were
A—5% acetonitrile, 5 mM ammonium acetate; B—95% acetonitrile, 1 mM
ammonium acetate. Water, acetonitrile, and ammonium acetate were Optima
grade. The gradient was 0–1 min at 17% B, 1–2 min 17–72% B, 2–7 min 72–74% B,
7–7.1 min 74–100% B, 7.1–8 min hold at 100% B, 8–8.1 min return to 17% B, and
8.1–10 min hold at 17% B. The autosampler was held at 7 °C and the column
compartment at 25 °C. The UHPLC system was coupled online with a Thermo Q
Exactive mass spectrometer (Bremen, Germany), scanning at 70,000 resolution in
the 350–550m/z range in negative ion mode. Negative electrospray ionization was
achieved with 4 kV spray voltage, 25 sheath gas, and 5 auxiliary gas. Data were
analyzed using Maven (Princeton, NJ, USA). Absolute quantitation was performed
by measuring the ratios of labeled and endogenous bile acids.
Intrahepatic mononuclear cell isolation. Buffers and solutions were kept at 37 °C
in a water bath. Solution 1: 50 ml EBSS (Gibco, Lafayette, CO, USA), 500 μl HEPES
(Sigma Aldrich, St. Louis, MO, USA), 9.5 mg EGTA (Sigma Aldrich, St. Louis, MO,
USA). Solution 2: 50 ml liver perfusion medium (Gibco, Lafayette, CO, USA) and
solution 3: 50 ml of liver digestion medium (Gibco, Lafayette, CO, USA). Mice were
kept on a heating pad and anesthetized with pentobarbital before performing a
midline laparotomy that extended to the ribcage. Then, the portal vein was iden-
tified and revealed and cannulated with a 24 gauge catheter that was connected to
plastic tubing for perfusion. Solution 1 was perfused at a rate of 2 ml/min until the
liver became opaque (approximately after 3 min of perfusion). Then, the inferior
vena cava was incised (to allow unimpaired outflow) before performing a ster-
notomy and clamping the superior vena cava. Subsequently, solutions 2 and 3 were
perfused for 6 min each. Liver was then carefully removed from the mouse and
placed into a chilled petri dish on ice with 5 ml of Williams medium (Thermo-
fisher, Waltham, MA, USA) containing high-performance FBS (Thermofisher,
Waltham, MA, USA) and 1% penicillin and streptomycin (Thermofisher, Wal-
tham, MA, USA). Liver capsule was incised, tissue gently swirled to liberate cells,
and subsequently passed over a 70 μm strainer into a chilled 50 ml tube, topped off
with Williams medium, and hepatocytes were pelleted by gravity for 30 min.
Supernatant (containing non-hepatocytes) was transferred to a fresh tube and
centrifuged for 5 min at 200 × g. Cell pellet was washed once in phosphate-buffered
saline (PBS) and then resuspendend in 1.6 ml of PBS and cell suspension mixed
into 2.4 ml of chilled 40% histodenz (Sigma Aldrich, St. Louis, MO, USA). One
milliliter of cold PBS was overlayed on top of the cell mixture and centrifuged at
2563 rpm for 20 min with the brake off. At the resulting interface of the PBS to
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gradient mononuclear cells were recovered and transferred to a tube containing 15
ml of PBS and pelleted at 1200 rpm for 5 min before further use for flow cytometry
or RNA extraction.
Flow cytometry. IHMCs were isolated from the liver as described above, washed,
pelleted, and resuspended in staining buffer, PBS with 1% Hyclone FBS (GE
Healthcare Life Sciences). An aliquot was removed, stained with trypan blue, and
counted via a hemocytometer66. All antibodies were purchased from BD Bios-
ciences (San Jose, CA, USA) and used at a diluton of 1:100. In brief, FcγR was first
blocked with anti-CD16/CD32 antibody at 4 °C for 10 min. Cells were then stained
for 30 min at 4 °C with the following antibodies: Ly6G-BV421 (Clone 1A8),
CD45R-BV421 (Clone RA3-6B2), CD3-BV421 (Clone 17A2), CD45-PE (Clone 30-
F11), F4/80-AF488 (Clone T45-2342), and CD11b-PE/Cy7 (Clone M1/70). All sort
tubes were pre-coated with FBS and contained ice-chilled sort buffer (PBS, 1 mM
EDTA, 25 mM HEPES, pH 7.3, and 50% FBS). Flow-assisted cell sorting was
conducted by staff at the University of Colorado Cancer Center Flow Cytometry
Core Facility and were performed on an XDP-100 device (Beckman Coulter). The
sorting strategy excluded debris and cell doublets using light scatter (forward
scatter and side scatter) while dead cells were excluded by DAPI+ (4',6-diamidino-
2-phenylindole) staining (1 mg/ml). Fluorescence minus one controls were used to
determine gating areas. Neutrophils, B cells, and T cells were excluded in the Dump
+ gate (Supplementary Fig. 1B). Dump− gate was then selected and CD45+
population was then segregated into monocytes (Mono: Dump−, CD45+, F4/80Lo,
CD11bHi), recruited macrophages (RecMO: Dump−, CD45+, F4/80Hi, CD11bHi),
and Kupffer cells (KCs: Dump−, CD45+, F4/80Hi, CD11bLo). All data analysis was
performed using Kaluza 1.5 (Beckman Coulter).
Statistical analysis. Gene expression was determined in triplicate for each mouse
in qRT-PCR assays. The average of the triplicate from each mouse was used to
generate the mean±standard error of mean for gene expression in each treatment
group; the number of animals in each group was generally 5–10 and are provided
in the text, figures, and/or legends. For cell experiments, gene expression was
determined in triplicate and results from one representative out of at least three
experiments are shown. One-way analysis of variance and Tukey’s correction for
multiple comparisons were used to determine statistical significance if more than
two groups were analyzed, otherwise Student’s ttest was used. If not otherwise
specified, a P value <0.05 was considered statistically significant.
Data availability. The data generated during and/or analyzed during the current
study are available from the corresponding authors on reasonable request.
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